Ivosidenib + mFOLFIRINOX in Patients with Resectable Pancreatic Adenocarcinoma

I'm Interested!

Please call
1-800-641-2422

A Phase I, Single-Center, Open Label, Dose De-escalation and Expansion Study Ivosidenib + mFOLFIRINOX in Patients with Resectable Pancreatic Adenocarcinoma

Sex at Birth: Any
Age: Adult (18 - 64), Older Adult (65+)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase I
Conditions Being Studied: Cancer - Pancreas

Study Purpose

This study is a single-arm, phase I trial, up to 16 participants with resectable PDA. The study will examine the efficacy of the mutant IDH1 inhibitor ivosidenib, in conjunction with standard-of-care mFOLFIRINOX in the neoadjuvant setting.

Principal Investigator
David Bajor MD

Department/Division
Cancer (Digestive System)

Locations

UH Seidman Cancer Center
11100 Euclid Avenue
Cleveland OH, 44106

Get Directions

UH IRB: STUDY20220093
StudyID: CASE7221
ClinicalTrials.gov: NCT05209074

I'm Interested!

Please call
1-800-641-2422

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-800-641-2422